Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors are investigated for cancer therapy, particularly in cells with BRCA1/2 mutations due to synthetic lethality.
• Previous findings indicated that NU1025, a PARP-1 inhibitor, was cytotoxic to BRCA1-positive BT-20 cells but not BRCA1-deficient SKBr-3 cells.
• This raised questions about the efficacy of other clinically evaluated PARP-1 inhibitors against BRCA1-deficient breast cancer cells.

Purpose of the Study:

• To compare the cytotoxicity of four clinically evaluated PARP-1 inhibitors (olaparib, rucaparib, iniparib, AZD2461) against breast cancer cells with differing BRCA1 statuses.
• To investigate the correlation between PARP-1 inhibitor efficacy, DNA damage, cell cycle progression, and proteomic profiles.
• To explore the potential of PARP-1 inhibitors beyond BRCA mutation carriers.

Main Methods:

• Cytotoxicity assays were performed on BRCA1-positive BT-20 and BRCA1-deficient SKBr-3 breast cancer cell lines.
• The effects of NU1025, olaparib, rucaparib, iniparib, and AZD2461 on cell viability, cell cycle progression, and DNA damage were assessed.
• Proteomic analysis was conducted to identify differentially expressed proteins in response to PARP-1 inhibition.

Main Results:

• Breast cancer cell sensitivity to PARP-1 inhibitors varied significantly.
• BRCA1-deficient SKBr-3 cells were largely insensitive to NU1025, olaparib, and rucaparib, while BRCA1-expressing BT-20 cells were sensitive to NU1025.
• Iniparib and AZD2461 demonstrated cytotoxicity against both cell lines, with AZD2461 notably affecting cell cycle progression. Efficacy correlated with DNA damage capacity.
• Proteomic analysis revealed distinct signatures between cell lines, with 197 proteins differentially expressed in NU1025-treated BT-20 cells.

Conclusions:

• The therapeutic efficacy of PARP-1 inhibitors is not uniform and depends on the specific inhibitor and the cancer cell's genetic background.
• Iniparib and AZD2461 show promise for treating both BRCA-deficient and BRCA-proficient breast cancers.
• These findings suggest that deficiencies in DNA repair pathways beyond BRCA1/2 may sensitize cells to PARP-1 inhibition, broadening potential therapeutic applications.